Biosynth
Stage
Merger | MergedAbout Biosynth
Biosynth is an accomplished firm with a successful history in the field of biochemicals for the diagnostics, pharmaceutical and chemical industries as well as food and environmental analysis. With its headquarters and main production in Switzerland and sites in Slovakia, the USA and China, Biosynth offers a product base of over 100’000 substances. Biosynth is an excellent partner for both industrial scale and research customers. Development projects, GMP, small and industrial scale manufacturing, as well as global sourcing are all core competencies of the Biosynth group.
Missing: Biosynth's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Biosynth's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Biosynth Patents
Biosynth has filed 14 patents.
The 3 most popular patent topics include:
- Immune system
- Immunology
- Vaccines
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/1/2022 | 2/21/2023 | Dietary supplements, Food additives, Acid salts, Ammonium compounds, Pyridines | Grant |
Application Date | 4/1/2022 |
|---|---|
Grant Date | 2/21/2023 |
Title | |
Related Topics | Dietary supplements, Food additives, Acid salts, Ammonium compounds, Pyridines |
Status | Grant |
Latest Biosynth News
May 10, 2023
10 May 2023 | News Addition of UK based peptide and antibody production facilities expands peptides and biologics business in UK and Europe Image credit: gettyimages Biosynth, a supplier of critical raw materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a leading independent producer of custom-made peptide and antibody tools, based in the UK and supplying researchers in the pharmaceutical, life science and academic sectors. CRB brings a wealth of expertise to Biosynth’s peptide division, which has existing operations in the US and the Netherlands. This includes leading expertise in complex peptide chemistry and fluorescent dye labelling. CRB also brings additional custom antibody capacity in Europe, to support customers through the generation of novel, complex or unusual mono- and poly-clonal antibodies unavailable in catalogs. Dr Urs Spitz, CEO and President of Biosynth, said, “Having a network of peptide sites at key locations, staffed by industry experts, allows us to best serve our customers throughout research and development and with the most complex and labelled peptides and high quality antibodies.” Emily Humphrys, Managing Director of Cambridge Research Biochemicals said, “As one of the longest established peptide companies, we have over 40 years of experience and are proud to have a strong track record for peptide and antibody excellence with our customers. We see great similarities in the approach that Biosynth already take in leading with science and customer focus.” Sign up for the editor pick and get articles like this delivered right to your inbox. Name *
Biosynth Frequently Asked Questions (FAQ)
Where is Biosynth's headquarters?
Biosynth's headquarters is located at Rietlistrasse 4, Staad.
What is Biosynth's latest funding round?
Biosynth's latest funding round is Merger.
Who are the investors of Biosynth?
Investors of Biosynth include Biosynth Carbosynth.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.